The story has been updated to clarify that the Oncotype DX breast cancer test will be conducted at Genomic Health's laboratory in California.

NEW YORK (GenomeWeb News) – Swiss-based diagnostics firm Unilabs said today that it is now offering Genomic Health's Oncotype DX breast cancer test at partner clinics and hospitals.

As part of its agreement with Genomic Health, physicians can send their patients' tissue samples to the Unilabs HIS laboratory. All tests will be sent to Genomic Health's centralized laboratory where the Oncotype DX testing will be done.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.